WBR0471: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (refreshing WBR questions)
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}} {{Alison}}
|QuestionAuthor= {{YD}} (Reviewed by  {{YD}} and  {{AJL}})
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Pathology
|MainCategory=Pathology
Line 8: Line 8:
|MainCategory=Pathology
|MainCategory=Pathology
|SubCategory=Hematology
|SubCategory=Hematology
|MainCategory=Pathology
|MainCategory=Pathology
|MainCategory=Pathology
|MainCategory=Pathology
|MainCategory=Pathology
Line 20: Line 21:
|MainCategory=Pathology
|MainCategory=Pathology
|SubCategory=Hematology
|SubCategory=Hematology
|Prompt=A 12-year-old African male, with a history of beta-thalassemia major, is brought to the physician's office for a routine bone marrow transplantation (BMT) work-up.  Prior to BMT, liver biopsy is performed to calculate Pesaro class risk for the patient. Which of the following findings is most likely observed upon liver biopsy?
|Prompt=A 12-year-old African-American boy with a history of beta-thalassemia major is brought to the physician's office for bone marrow transplantation (BMT) work-up. The patient Liver biopsy is performed to calculate Pesaro class risk for the patient prior to BMT. Which of the following findings is most likely observed on liver biopsy?
|Explanation=[[Beta-thalassemia major]], an inherited hematological disorder, is characterized by the reduced (or absent) production of a [[beta-globin]] chain of [[hemoglobin]] proteins, resulting from a point mutation in [[splice sites]] or [[promoter]] sequences. It manifests as severe [[anemia]], and subsequent ineffective [[erythropoiesis]], which eventually cause [[bone marrow]] expansion.
|Explanation=[[Beta-thalassemia major]] is an inherited hemoglobinopathy characterized by the absent production of a [[beta-globin]] chain of the [[hemoglobin]] tetramer. It commonly results from a point mutation in [[splice sites]] or [[promoter]] sequences. Beta-thalassemia major manifests as severe [[anemia]] and subsequent ineffective [[erythropoiesis]], which eventually cause [[bone marrow]] expansion. The majority of cases of [[Beta-thalassemia]] major are reported in the Mediterranean region, Africa, and Southeast Asia. In individuals with [[beta-thalassemia major]], chronic [[red cell transfusions]] are considered the optimal therapy for symptomatic management. However, repeated transfusions are associated with [[iron overload]], which requires the administration of iron-chelating therapy, frequently with [[deferoxamine]]. Bone marrow transplant is the only cure for patients with [[beta-thalassemia major]].  Pesaro classification, a detailed pre-BMT evaluation often used to predict outcomes following transplant, evaluates three independent risk factors: [[Hepatomegaly]] on physical examination, [[portal fibrosis]] on [[liver biopsy]], and adequacy of iron chelation.
Cases of [[Beta-thalassemia]] major are often reported in the Mediterranean region, Africa, and Southeast Asia.  
|AnswerA=Hepatocyte accumulation of copper
 
In individuals with [[beta-thalassemia major]], chronic [[red cell transfusions]] are considered the optimal therapy for relieving symptoms. Repeated transfusions are associated with [[iron overload]], requiring the administration of iron-chelating therapy, frequently with [[deferoxamine]].  
 
Bone marrow transplant is considered the only cure for patients with [[beta-thalassemia major]].  Pesaro classification, a detailed pre-BMT evaluation often used to predict outcomes following transplant, evaluates three independent risk factors: [[Hepatomegaly]] on physical examination, [[portal fibrosis]] on [[liver biopsy]], and adequacy of iron chelation.
 
|EducationalObjectives= [[Beta-thalassemia major]], a hematological inherited disorder, is characterized by the absent or reduced production of beta-chains of hemoglobin proteins.  Recurrent [[red cell transfusions]], a symptomatic treatment, are associated with iron accumulation, which necessitates the administration of iron-chelation therapy.
|References= Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Eng J Med. 1993;329:840-4.
 
|AnswerA=Hepatocyte accumulation of cupper
|AnswerAExp=The accumulation of cupper frequently occurs in [[Wilson's disease]].
|AnswerAExp=The accumulation of cupper frequently occurs in [[Wilson's disease]].
|AnswerB=Hepatocyte accumulation of iron
|AnswerB=Hepatocyte accumulation of iron
Line 41: Line 33:
|AnswerE=Hepatocyte accumulation of lipids
|AnswerE=Hepatocyte accumulation of lipids
|AnswerEExp=[[Hepatic steatosis]], or accumulation of lipids in the liver, is associated with chronic [[alcoholism]].
|AnswerEExp=[[Hepatic steatosis]], or accumulation of lipids in the liver, is associated with chronic [[alcoholism]].
|EducationalObjectives=[[Beta-thalassemia major]], a hematological inherited disorder, is characterized by the absent or reduced production of beta-chains of hemoglobin proteins.  Recurrent [[red cell transfusions]], a symptomatic treatment, are associated with iron accumulation, which necessitates the administration of iron-chelation therapy.
|References=Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Eng J Med. 1993;329:840-4.
|RightAnswer=B
|RightAnswer=B
|WBRKeyword=beta-thalassemia, Mediterranean, inherited, liver, hepatocyte, iron accumulation, deferoxamine, bone marrow transplant, Pesaro, accumulation, transfusions, BMT
|WBRKeyword=Beta-thalassemia, Mediterranean, inherited, Liver, Hepatocyte, Iron accumulation, Deferoxamine, Bone marrow transplant, Pesaro, Transfusions, BMT
|Approved=Yes
|Approved=Yes
}}
}}

Latest revision as of 00:41, 28 October 2020
Author [[PageAuthor::Yazan Daaboul, M.D. (Reviewed by Yazan Daaboul, M.D. and Alison Leibowitz [1])]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pathology
Sub Category SubCategory::Hematology
Prompt [[Prompt::A 12-year-old African-American boy with a history of beta-thalassemia major is brought to the physician's office for bone marrow transplantation (BMT) work-up. The patient Liver biopsy is performed to calculate Pesaro class risk for the patient prior to BMT. Which of the following findings is most likely observed on liver biopsy?]]
Answer A AnswerA::Hepatocyte accumulation of copper
Answer A Explanation [[AnswerAExp::The accumulation of cupper frequently occurs in Wilson's disease.]]
Answer B AnswerB::Hepatocyte accumulation of iron
Answer B Explanation AnswerBExp::The accumulation of iron frequently occurs following recurrent transfusions, administered to patients with thalassemia major or hemochromatosis.
Answer C AnswerC::Hepatocyte accumulation of lead
Answer C Explanation AnswerCExp::Lead does not frequently accumulate in the livers of individuals with thalassemia major.
Answer D AnswerD::Hepatocyte accumulation of calcium
Answer D Explanation AnswerDExp::Thalassemia major is not associated with calcium accumulation.
Answer E AnswerE::Hepatocyte accumulation of lipids
Answer E Explanation [[AnswerEExp::Hepatic steatosis, or accumulation of lipids in the liver, is associated with chronic alcoholism.]]
Right Answer RightAnswer::B
Explanation [[Explanation::Beta-thalassemia major is an inherited hemoglobinopathy characterized by the absent production of a beta-globin chain of the hemoglobin tetramer. It commonly results from a point mutation in splice sites or promoter sequences. Beta-thalassemia major manifests as severe anemia and subsequent ineffective erythropoiesis, which eventually cause bone marrow expansion. The majority of cases of Beta-thalassemia major are reported in the Mediterranean region, Africa, and Southeast Asia. In individuals with beta-thalassemia major, chronic red cell transfusions are considered the optimal therapy for symptomatic management. However, repeated transfusions are associated with iron overload, which requires the administration of iron-chelating therapy, frequently with deferoxamine. Bone marrow transplant is the only cure for patients with beta-thalassemia major. Pesaro classification, a detailed pre-BMT evaluation often used to predict outcomes following transplant, evaluates three independent risk factors: Hepatomegaly on physical examination, portal fibrosis on liver biopsy, and adequacy of iron chelation.

Educational Objective: Beta-thalassemia major, a hematological inherited disorder, is characterized by the absent or reduced production of beta-chains of hemoglobin proteins. Recurrent red cell transfusions, a symptomatic treatment, are associated with iron accumulation, which necessitates the administration of iron-chelation therapy.
References: Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Eng J Med. 1993;329:840-4.]]

Approved Approved::Yes
Keyword WBRKeyword::Beta-thalassemia, WBRKeyword::Mediterranean, WBRKeyword::inherited, WBRKeyword::Liver, WBRKeyword::Hepatocyte, WBRKeyword::Iron accumulation, WBRKeyword::Deferoxamine, WBRKeyword::Bone marrow transplant, WBRKeyword::Pesaro, WBRKeyword::Transfusions, WBRKeyword::BMT
Linked Question Linked::
Order in Linked Questions LinkedOrder::
Retrieved from "https://www.wikidoc.org/index.php?title=WBR0471&oldid=1671730"